TABLE 1.
The clinical characteristics and pathological features in the overall population and after stratification by statin use
| Median (range) or n (%) variable (n) | Total | Statin | No statin | P |
|---|---|---|---|---|
| Age at surgery, years (1351) | 59 (37–76) | 61 (43–76) | 58 (37–76) | <0.001 |
| PSA level, ng/mL (1343) | 4.9 (0.1–63.6) | 4.8 (0.1–24) | 5.0 (0.2–63.6) | 0.002 |
| Biopsy Gleason score ≥7 (1342) | 433 (31.5) | 157 (31.5) | 265 (31.4) | 1.000 |
| Clinical stage <T2 (1348) | 1009 (74.9) | 379 (75.5) | 630 (74.5) | 0.700 |
| PSA velocity, ng/mL/year (616) | 1.32 (−251.4–41.5) | 1.57 (−52.1–28.3) | 1.25 (−251.4–41.5) | 0.160 |
| PSA velocity >2 ng/mL/year (616) | 237 (38.5) | 99 (40.6) | 138 (37.1) | 0.400 |
| Body mass index, kg/m2 (1347) | 27.0 (17.4–44.6) | 27.3 (19.3–44.1) | 26.6 (17.4–44.6) | 0.001 |
| Pathology at RP | ||||
| Organ-confined (1339) | 1077 (80.4) | 406 (81.2) | 671 (80.0) | 0.620 |
| Positive margins (1349) | 221 (16.4) | 69 (13.7) | 152 (18.0) | 0.048 |
| Extracapsular extension (1349) | 251 (18.6) | 87 (17.3) | 164 (19.4) | 0.350 |
| Seminal vesicle invasion (1348) | 57 (4.2) | 15 (3.0) | 42 (5.0) | 0.093 |
| Lymph node metastases (1348) | 9 (0.7) | 2 (0.4) | 7 (0.8) | 0.500 |
| Gleason score ≥7 (1345) | 653 (48.6) | 234 (46.8) | 419 (49.6) | 0.340 |
| Prostate weight, g (1340) | 47.3 (16.0–557.3) | 48.1 (18.5–254.7) | 46.8 (16.0–557.3) | 0.260 |
| % cancer (1276) | 8 (0.1–90) | 7.0 (0.1–75.0) | 9.0 (0.1–90.0) | 0.049 |
| Tumour volume, mL (1276) | 3.7 (0.04–71.2) | 3.5 (0.06–50.2) | 3.7 (0.04–71.2) | 0.032 |